June 8, 2020 / 7:38 PM / a month ago

BRIEF-Oncology Venture Acquires Full Control Of Dovitinib Program

June 8 (Reuters) - Oncology Venture A/S:

* REG-PRESS RELEASE ONCOLOGY VENTURE ACQUIRES FULL CONTROL OF DOVITINIB PROGRAM

* ONCOLOGY VENTURE A/S - ACQUIRED REMAINING 37% OWNERSHIP IN ITS PRIORITY DOVITINIB PROGRAM FROM INVESTOR SASS & LARSEN APS

* ONCOLOGY VENTURE- PRICE OF REMAINING 37% OV-SPV2 APS IS AGREED TO SEK 36 MILLION, POTENTIAL ROYALTY PAYMENT OF 10 % FOR 1ST 24 MONTHS AFTER DEAL SIGNATURE

* ONCOLOGY VENTURE A/S - PAYMENT OF SEK 36 MILLION IS MADE BY CONVERSION OF PAYMENT INTO ONCOLOGY VENTURE A/S SHARES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below